OptiNose (OPTN) Competitors $9.60 0.00 (0.00%) As of 05/21/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OPTN vs. ITOS, RVNC, FULC, CKPT, VIGL, RZLT, ARCT, ADCT, RAPP, and ORGOShould you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), Vigil Neuroscience (VIGL), Rezolute (RZLT), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Rapport Therapeutics (RAPP), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. OptiNose vs. Its Competitors iTeos Therapeutics Revance Therapeutics Fulcrum Therapeutics Checkpoint Therapeutics Vigil Neuroscience Rezolute Arcturus Therapeutics ADC Therapeutics Rapport Therapeutics Organogenesis iTeos Therapeutics (NASDAQ:ITOS) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Do institutionals and insiders hold more shares of ITOS or OPTN? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 2.3% of OptiNose shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ITOS or OPTN more profitable? iTeos Therapeutics has a net margin of 0.00% compared to OptiNose's net margin of -41.16%. OptiNose's return on equity of 0.00% beat iTeos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% OptiNose -41.16%N/A -27.42% Do analysts rate ITOS or OPTN? iTeos Therapeutics presently has a consensus price target of $15.86, indicating a potential upside of 57.94%. OptiNose has a consensus price target of $9.00, indicating a potential downside of 6.25%. Given iTeos Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe iTeos Therapeutics is more favorable than OptiNose.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14OptiNose 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, ITOS or OPTN? OptiNose has higher revenue and earnings than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M10.98-$112.64M-$3.04-3.30OptiNose$81.86M1.19-$35.48M-$3.00-3.20 Does the media refer more to ITOS or OPTN? In the previous week, iTeos Therapeutics had 24 more articles in the media than OptiNose. MarketBeat recorded 24 mentions for iTeos Therapeutics and 0 mentions for OptiNose. iTeos Therapeutics' average media sentiment score of 0.15 beat OptiNose's score of 0.00 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment iTeos Therapeutics Neutral OptiNose Neutral Does the MarketBeat Community believe in ITOS or OPTN? OptiNose received 200 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 73.13% of users gave iTeos Therapeutics an outperform vote while only 62.88% of users gave OptiNose an outperform vote. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes4973.13% Underperform Votes1826.87% OptiNoseOutperform Votes24962.88% Underperform Votes14737.12% Which has more risk and volatility, ITOS or OPTN? iTeos Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. SummaryiTeos Therapeutics beats OptiNose on 12 of the 18 factors compared between the two stocks. Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPTN vs. The Competition Export to ExcelMetricOptiNosePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.22M$6.92B$5.59B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.298.8527.2120.00Price / Sales1.19261.39411.62157.76Price / CashN/A65.8538.2534.64Price / Book-0.836.597.114.70Net Income-$35.48M$144.20M$3.24B$248.05M7 Day PerformanceN/A3.53%2.54%2.51%1 Month Performance1.91%10.82%8.76%6.17%1 Year Performance-48.39%3.87%31.37%13.72% OptiNose Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTNOptiNose1.8066 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190ITOSiTeos Therapeutics3.8712 of 5 stars$10.01-0.1%$15.86+58.4%-38.7%$383.12M$35M-3.1890Insider TradeHigh Trading VolumeRVNCRevance Therapeutics2.5937 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500FULCFulcrum Therapeutics0.4646 of 5 stars$6.96+1.2%$6.29-9.7%-7.7%$375.69M$80M-22.45100Analyst RevisionCKPTCheckpoint Therapeutics2.538 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210VIGLVigil Neuroscience4.0565 of 5 stars$7.93+0.5%$10.80+36.2%+71.6%$370.11MN/A-3.8540Positive NewsRZLTRezolute2.7243 of 5 stars$4.22+2.4%$12.14+187.7%-18.5%$360.89MN/A-3.4640Positive NewsHigh Trading VolumeARCTArcturus Therapeutics3.2544 of 5 stars$12.81+2.2%$53.50+317.6%-61.6%$347.42M$131.27M-5.77180News CoveragePositive NewsAnalyst RevisionGap UpADCTADC Therapeutics2.8524 of 5 stars$3.50+13.3%$7.75+121.3%+13.2%$347.32M$75.82M-1.47310News CoveragePositive NewsAnalyst RevisionGap DownHigh Trading VolumeRAPPRapport Therapeutics1.7539 of 5 stars$9.40+13.7%$32.67+247.5%N/A$343.08MN/A-2.72N/APositive NewsHigh Trading VolumeORGOOrganogenesis4.6303 of 5 stars$2.66-2.9%$5.50+106.8%+20.4%$337.43M$458.76M-44.33950Positive NewsAnalyst Revision Related Companies and Tools Related Companies iTeos Therapeutics Alternatives Revance Therapeutics Alternatives Fulcrum Therapeutics Alternatives Checkpoint Therapeutics Alternatives Vigil Neuroscience Alternatives Rezolute Alternatives Arcturus Therapeutics Alternatives ADC Therapeutics Alternatives Rapport Therapeutics Alternatives Organogenesis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPTN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
